Hospital Services


An image of the word "WHY" spelled with white powder with 2 Texwipe® swabs framing it on a blue background.


Eagle excels at helping sterile and nonsterile hospital compounding facilities identify risks, challenges, and opportunities by suggesting and helping you implement cost-effective science-based solutions. Our personnel’s experience spans the compounding and pharmaceutical industry with expertise in USP <795> Pharmaceutical Compounding – Nonsterile Preparations, USP <797> Pharmaceutical Compounding – Sterile Preparations, USP <800> Hazardous Drugs – Handling in Healthcare Settings, and Current Good Manufacturing Practices (CGMP).

It is Eagle’s goal to add value to your operation and make compliance convenient and efficient. Choose Eagle as your hospital’s compounding facility support partner and let our experience work for you.

Environmental Monitoring Solutions

Environmental monitoring (EM) is fundamental to assuring that aseptic processing areas are maintained in an adequate state of control. USP <797> revisions, effective November 1, 2023, have increased the monitoring requirements of air and surfaces for microbial contamination. However, environmental monitoring extends beyond that. Revisions to the USP <795> and <797> compounding chapters make USP <800> compendially applicable which introduces environmental wipe sampling for hazardous drug (HD) surface residue. Environmental monitoring for microbial contamination and HD residue is essential for assuring compounded product quality and personnel safety.

SurfaceShield Wipe Sampling and Cleaning Verification Kit

Stacked shipping boxes of SurfaceShield SurfaceShield Wipe Sampling and Cleaning Verification Kit

SurfaceShield is a wipe sampling kit for the detection of drugs on surfaces at hospitals, pharmacies, and other healthcare institutions. Sampling with this kit is a fast, easy, and convenient method for verifying the efficacy of your decontamination and cleaning program, evaluating personnel work practices, and supporting the adequacy of engineering controls.

Learn MorePurchase

Back to Top


90 mm Tryptic Soy Agar Plates

Two stacked 90 mm Tryptic Soy Agar Plates, one with four plates and the other with three. One TSA plate laying at an angle acoss the shorter of the two stacks so the viwer can see inside the

Our 90 mm TSA (tryptic soy agar) settle plates supplemented with Lecithin and Tween 80 to neutralize the effects of disinfectants are suitable for both active and passive air sampling as well as gloved fingertip sampling. Our plates offer the benefit of room-temperature storage, locking lids, and are triple-wrapped for efficient movement throughout ISO-classified areas. A certificate of growth promotion from the manufacturer is provided with all orders. Eagle performs growth promotion testing on all incoming media and a certificate of our results is available upon request.

Back to Top


65 mm Tryptic Soy Agar Plates

Blue gloved hand holding a 65mm Surface/Contact Plates – Tryptic Soy Agar (TSA).

Our 65 mm TSA (tryptic soy agar) contact plates supplemented with Lecithin and Tween 80 to neutralize the effects of disinfectants are suitable for surface, active air, and personnel monitoring. Our plates offer the benefit of room-temperature storage, locking lids, and are triple-wrapped for efficient movement throughout ISO-classified areas. A certificate of growth promotion from the manufacturer is provided with all orders. Eagle performs growth promotion testing on all incoming media and a certificate of our results is available upon request.  



Back to Top


Category 3 CSP Beyond-Use Dating Through Stability Studies

A beyond-use date (BUD) is the date, or hour and date, beyond which a compounded preparation, sterile or nonsterile, cannot be used and should be set based on the date, or date and time, of compounding. The revisions to the USP <795> and <797> compounding chapters effective November 1, 2023, have updated the BUD limits for both sterile and nonsterile compounded preparations.

Category 3 CSP

Two chemist discussing the BUD of a compounding sample.

Beyond Use Dates (BUDs) can be extended for compounded nonsterile preparations (CNSPs) up to a maximum of 180 days when supported by stability studies performed utilizing a validated, stability-indicating method. The longest BUDs for compounded sterile preparations (CSPs) are limited to those compounded in accordance with Category 3 CSP requirements and must be supported by stability studies. Stability studies must be performed for the exact formulation and in its final container-closure system to evaluate the extent that a product retains its quality throughout its intended shelf-life. Additionally, USP <51> Antimicrobial Effectiveness Testing must be performed for preserved, aqueous dosage forms.

Back to Top


Finished Drug Product Release Testing

Finished pharmaceutical products at release are subjected to testing for their chemical and microbial quality attributes to ensure the identity, strength, purity, and efficacy of the product.  

Testing Methods

Microbiologist utilizing EagleTrax.

For finished drug product release testing, the chemical analyses include but are not limited to testing for identification, assay/potency, impurities/degradants, physicochemical properties, content uniformity, and dissolution. Microbiology testing includes but is not limited to testing the product for sterility, endotoxins, bioburden, objectionable microorganisms, and antimicrobial effectiveness. Additionally, the testing may also include checking physical characteristics such as re-suspendibility, container-closure integrity and particulate matters. The testing methods used for any of the aforementioned analyses must be accurate, precise, and reproducible.

Back to Top

Consulting Services

Our consulting team is comprised of professionals spanning the healthcare and pharmaceutical industry with expertise in sterile and nonsterile compounding, current good manufacturing practices (CGMP), chemistry, microbiology, and quality assurance.

Let Our Experience Work For You

Picture collage of Patel (Ph.D.), Jacqueline Esqueda (PharmD), David Hussong (Ph.D.), Lisa Johnson (BS), Ross Caputo (Ph.D.), Mary Moriva, Jeff Gloyer (MS), Frank Allen (BS) and Robert Byrne (Ph.D.).

Our experts can assist you in all areas related to USP chapters <795> Pharmaceutical Compounding – Nonsterile Preparations, <797> Pharmaceutical Compounding – Sterile Preparations, and <800> Hazardous Drugs – Handling in the Healthcare Setting, including but not limited to:

  • Personnel training and qualification including aseptic training
  • Development of critical systems including environmental monitoring program, cleaning and disinfection program, and media-fill testing
  • Terminal sterilization cycle development and validation
  • Building/cleanroom facility design review
  • Gap analysis audit
  • SOP and quality system review and development
  • Regulatory response and remediation
  • Development of a hazardous drug wipe sampling program including acceptable surface limits

Back to Top

Cleanroom Certification 

Eagle knows that you rely on your equipment to perform as expected. These instruments operate as a safeguard for the quality of your products and for the well-being of your staff. With us, you will feel confident that your equipment is operating as intended.  

Dedication To Precision
Engineer, Director of Operations Frank Allen, conducts testing in an Eagle cleanroom.

To ensure your cleanroom is operating properly, a full cleanroom inspection is conducted. This inspection includes HEPA Filter Integrity Testing, Differential Pressure Measurement, Air Change Per Hour Measurement and Calculation, and more. Learn More

Back to Top

Smoke Studies

Smoke studies are a key qualification to ensure that your products are free from contamination and that your staff is operating in a safe environment.

Cleanroom Inspection

A Smoke Study being performed inside an ISO 5 hood under dynamic conditions.

Eagle’s smoke studies include a Static Air Visualization study and a Dynamic Air Visualization study with video and report. With Eagle’s engineers performing your smoke study, you and your staff will feel confident that your equipment is operating.  Learn More

Back to Top

Additional Testing Services for Hospital Compounding 

The experience and knowledge of our team, outstanding customer service, and state-of-the-equipment make Eagle the best choice for all of your testing needs.

“Our desire, dedication, and discipline to ensure that patient safety is at the forefront of everything we do and our holistic approach to resolving your compliance needs make Eagle a truly unique organization.”   President and CEO, Ross A. Caputo


Media-Fill Testing Services

Media-fill testing should be performed by all sterile compounding facilities to evaluate and/or qualify an operator’s aseptic technique and challenge the aseptic process. The aseptic process is simulated utilizing soybean-casein digest, a liquid media supporting and promoting microbial growth, under worst-case conditions.

Eagle offers the following testing and advisory services to satisfy the USP <797> requirements for media-fill testing:

  • Media-fill protocol development
  • Incubation and evaluation of media-filled units
  • Microbial identification growth in media-filled units
  • Post media-fill growth promotion testing

Pricing Request | Testing Services | Microbiological Department Services

Microbial Identification (subculture isolation and gram staining)

This test identifies microorganisms isolated during different phases of manufacturing and quality testing to the genus/species level using DNA sequencing.

Pricing Request | Testing Services

Potency Testing


Potency testing measures the concentration of the active ingredient at a specific point in time. Pricing Request | Testing Services


Potency Testing Services and Turnaround Time Table


USP <51> Antimicrobial Effectiveness

Sterile articles packaged in multi-dose containers must be free of microorganisms throughout their entire shelf life. Due to the potential for the introduction of microorganisms through the repeated withdrawal of individual doses, sterile products that are packaged in multi-dose containers should contain an antimicrobial preservative. However, the concentration of an added antimicrobial preservative can be kept to a minimum if the ingredients of the compounded formulation possess an intrinsic antimicrobial activity. Antimicrobial effectiveness, whether inherent in the product or as a result of an antimicrobial preservative, must be demonstrated through USP <51> antimicrobial effectiveness testing.  Pricing Request | Testing Services

USP <71> Sterility Testing

USP <71> outlines the compendial requirements for sterility testing that must be followed in order to be able to claim that the results of the test provide evidence that the product is sterile.  Pricing Request | Testing Services

Related Resources:

USP <71> Method Suitability Testing

USP <71> Method Suitability Testing (MST) must be performed prior to being able to claim that the results of a USP <71> sterility test provide evidence of a preparation’s sterility. Method Suitability Testing only needs to be completed once for each compounded formulation, and consists of two parts: i) a suitability test that confirms that the growth media used for sterility testing supports the growth of certain microorganisms and ii) a validation test that demonstrates that no components of the compounded preparation inhibit microbial growth.  Pricing Request | Testing Services

USP <85> Bacterial Endotoxin Testing

As bacterial endotoxins can pose health and safety hazards to patients, USP <85> requires bacterial endotoxin testing to detect and quantify the presence of endotoxins from Gram-negative bacteria in sterile compounds. To assure patient safety, the quantity of bacterial endotoxins may not exceed threshold limits defined in USP <85>. For each bacterial endotoxin test, inhibition validation testing is performed. This testing confirms that there are no components of the formulation that will interfere with the bacterial endotoxin test and that the testing used is sensitive enough to provide meaningful, accurate data.  Pricing Request | Testing Services

Related Resource:

USP <788> or USP <789> Particulate Count

Solutions must be essentially free from observable particulate matter. Due to the small amount of material and the heterogenous composition that particulate matter represents, it cannot be quantitated by chemical analysis alone. Pricing Request | Testing Services

USP <1207> Container-Closure Integrity Testing

Container-closure integrity testing demonstrates the ability of the container-closure system to maintain the integrity of its microbial barrier throughout the entire shelf-life of a product. Eagle utilizes a pressure decay to test container-closure integrity, which is one of the deterministic methods recommended by USP <1207>. As sterility is an event-related occurrence, container-closure integrity testing is performed to support the claim that the sterile containers in which the preparation is packaged are capable of maintaining the sterility of the product throughout its shelf life.  Pricing Request | Testing Services

USP <1223> Validation of Alternative Microbiological Methods | ScanRDI® Rapid Microbial Method Sterility Test

ScanRDI fulfills the method suitability requirement as outlined in USP <1223>. The SCANRDI® is a unique alternative technology that enables Eagle to deliver sterility testing results in 2 business days, allowing sterile compounding facilities to release product faster than when utilizing the compendial USP <71>  method. SCANRDI® has revolutionized rapid microbial detection and its combination of speed and sensitivity remains unrivaled to this day(a)Pricing Request | Testing Services

Related Resources:


* SCANRDI® is a registered trademark of Biomeriuex.

** Method currently not accepted in some states.

† Standard processing time is 2 business days. 1 business day turnaround time is available through our RUSH service. Please call Eagle customer care for up-to-date scheduling upon sample submission.

(a) Biomeriuex – ScanRDI Rapid Microbial Detection – http://www.biomeriuex-usa.com


Patient, Personnel, and Product Safety Solutions for Hospital Compounding

Prioritize patient, personnel, and product safety solutions for hospital compounding pharmacy. Download this guide to learn more that environmental monitoring, beyond-use dating, release testing, and more.

Safety Solutions For Hospital Compounding

Yes, I’d like to advance patient and worker safety and strengthen environmental protections.

Verified by MonsterInsights